678 related articles for article (PubMed ID: 9305652)
1. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.
Wu X; Liu H; Xiao H; Conway JA; Hunter E; Kappes JC
EMBO J; 1997 Aug; 16(16):5113-22. PubMed ID: 9305652
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein.
Liu H; Wu X; Xiao H; Conway JA; Kappes JC
J Virol; 1997 Oct; 71(10):7704-10. PubMed ID: 9311854
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
4. Complementation of integrase function in HIV-1 virions.
Fletcher TM; Soares MA; McPhearson S; Hui H; Wiskerchen M; Muesing MA; Shaw GM; Leavitt AD; Boeke JD; Hahn BH
EMBO J; 1997 Aug; 16(16):5123-38. PubMed ID: 9305653
[TBL] [Abstract][Full Text] [Related]
5. Coding sequences upstream of the human immunodeficiency virus type 1 reverse transcriptase domain in Gag-Pol are not essential for incorporation of the Pr160(gag-pol) into virus particles.
Chiu HC; Yao SY; Wang CT
J Virol; 2002 Apr; 76(7):3221-31. PubMed ID: 11884546
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
Liao WH; Wang CT
Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
Wu X; Liu H; Xiao H; Conway JA; Kappes JC
J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
[TBL] [Abstract][Full Text] [Related]
8. A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions.
Kulkosky J; BouHamdan M; Geist A; Pomerantz RJ
Virology; 1999 Mar; 255(1):77-85. PubMed ID: 10049823
[TBL] [Abstract][Full Text] [Related]
9. The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein.
Shehu-Xhilaga M; Hill M; Marshall JA; Kappes J; Crowe SM; Mak J
J Virol; 2002 May; 76(9):4331-40. PubMed ID: 11932399
[TBL] [Abstract][Full Text] [Related]
10. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
Accola MA; Strack B; Göttlinger HG
J Virol; 2000 Jun; 74(12):5395-402. PubMed ID: 10823843
[TBL] [Abstract][Full Text] [Related]
11. A domain directly C-terminal to the major homology region of human immunodeficiency type 1 capsid protein plays a crucial role in directing both virus assembly and incorporation of Gag-Pol.
Chien AI; Liao WH; Yang DM; Wang CT
Virology; 2006 Apr; 348(1):84-95. PubMed ID: 16442581
[TBL] [Abstract][Full Text] [Related]
12. Analysis of human immunodeficiency virus type 1 containing HERV-K protease.
Padow M; Lai L; Fisher RJ; Zhou YC; Wu X; Kappes JC; Towler EM
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1973-80. PubMed ID: 11153080
[TBL] [Abstract][Full Text] [Related]
13. Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.
Lavallée C; Yao XJ; Ladha A; Göttlinger H; Haseltine WA; Cohen EA
J Virol; 1994 Mar; 68(3):1926-34. PubMed ID: 8107252
[TBL] [Abstract][Full Text] [Related]
14. Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo.
Mulky A; Sarafianos SG; Arnold E; Wu X; Kappes JC
J Virol; 2004 Jul; 78(13):7089-96. PubMed ID: 15194785
[TBL] [Abstract][Full Text] [Related]
15. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses.
Selig L; Pages JC; Tanchou V; Prévéral S; Berlioz-Torrent C; Liu LX; Erdtmann L; Darlix J; Benarous R; Benichou S
J Virol; 1999 Jan; 73(1):592-600. PubMed ID: 9847364
[TBL] [Abstract][Full Text] [Related]
16. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.
Wu X; Liu H; Xiao H; Kim J; Seshaiah P; Natsoulis G; Boeke JD; Hahn BH; Kappes JC
J Virol; 1995 Jun; 69(6):3389-98. PubMed ID: 7745685
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutant.
Huang M; Zensen R; Cho M; Martin MA
J Virol; 1998 Mar; 72(3):2047-54. PubMed ID: 9499059
[TBL] [Abstract][Full Text] [Related]
19. Virion-targeted viral inactivation: new therapy against viral infection.
Okui N; Kitamura Y; Kobayashi N; Sakuma R; Ishikawa T; Kitamura T
Mol Urol; 2001; 5(2):59-66. PubMed ID: 11690549
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.
Yu XF; Dawson L; Tian CJ; Flexner C; Dettenhofer M
J Virol; 1998 Apr; 72(4):3412-7. PubMed ID: 9525672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
